Pharma-Data focuses to regulatory affairs, business and product development offering fully integrated, customized to sponsors, state-of-the-art and cost effective services.
Following the continuously complexity of the pharmaceutical legislation and demands, Pharma-Data is focused on the provision of:
High-quality, state-of-the-art registration dossiers for pharmaceutical products
Contract development of pharmaceuticals products.
regulatory affairs consulting.
Business development services.
Licensing opportunities (-in & -out).
Our main goal is to offer top services to our partners, succeeding the establishment of critical agreements and win-win collaborations between parties.
Target Partners & Collaborations
Pharma-Data is seeking for partners and customers for new product developments, co-developments, dossier updates, tech-transfers and development of innovative technologies (hybrid applications, generic-plus etc.).
Technologies / Services offered or sought
Extensive research for USE, API and FORMULATION patents (in-house and/or by specialized patent attorneys)
Thorough investigation in the best facility for Drug Product pilot and commercial batches contract manufacturing
Formulation development
Design and Validation of Analytical methods (according to ICH guidelines)
Robust and cost-effective manufacturing process development and optimization
Process validation (ICH guidelines)
Stress Studies
Stability studies (ICH guidelines)
Compatibility studies/ in-use stability studies
Bioequivalence studies (using the highest skilled specialized CROs worldwide)
Dossier compilation and submission
Preparation and follow-up of National, MRP and DPC applications
Pharma-Data can work as one-stop CRO from API to eCTD dossier, galenical development, analytical services, ICH stability to our ISO and EU-GMP approved and soon FDA compliant R&D laboratory.
Clients & Collaborations (INTERNATIONAL)
Pharma-Data is seeking for partners and customers for new product developments, co-developments, dossier updates, tech-transfers and development of innovative technologies (hybrid applications, generic-plus etc.).